Quick Answer
GeoVax Labs, Inc. reported Cash and Equivalents of $5.51 million for fiscal year 2024.
GeoVax Labs, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $5.51M | -14.7% |
| 2023 | $6.45M | -76.6% |
| 2022 | $27.61M | +141.7% |
| 2021 | $11.42M | +15.6% |
| 2020 | $9.88M | +3388.3% |
| 2019 | $283.3K | +9.1% |
| 2018 | $259.7K | -17.0% |
| 2017 | $312.7K | -31.1% |
| 2016 | $454.0K | -57.2% |
| 2015 | $1.06M | -3.7% |
| 2014 | $1.10M | -56.2% |
| 2013 | $2.51M | +142.7% |
| 2012 | $1.04M | -11.3% |
| 2011 | $1.17M | +8.2% |
| 2010 | $1.08M | -69.3% |
| 2009 | $3.52M | +60.5% |
| 2008 | $2.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.01M | -41.7% | +61.9% |
| June 30, 2025 | $3.09M | +98.1% | -58.4% |
| March 31, 2025 | $7.44M | +867.5% | +35.1% |
| December 31, 2024 | $5.51M | -14.7% | -35.9% |
| September 30, 2024 | $8.59M | -32.3% | +450.2% |
| June 30, 2024 | $1.56M | -91.2% | +103.1% |
| March 31, 2024 | $768.9K | -96.8% | -88.1% |
| December 31, 2023 | $6.45M | -76.6% | -49.1% |
- GeoVax Labs, Inc. showed a decrease of -14.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2024 period, GeoVax Labs, Inc.’s cash and equivalents has grown by 151.3% (from $2.19 million to $5.51 million).
- The most recent figure is from GeoVax Labs, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: